Clinical Trial Update: Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of intravenous ACZ885 (canakinumab) in patients with wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Wet Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED